Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FURIN | P09958 | 1/20 | 0.44 |
| ▸ | TSLP | Q969D9 | 2/20 | 0.43 |
| ▸ | PLK1 | P53350 | 1/20 | 0.42 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.40 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.40 |
| ▸ | MC1R | Q01726 | 4/20 | 0.39 |
| ▸ | MC4R | P32245 | 3/20 | 0.39 |
| ▸ | PLG | P00747 | 1/20 | 0.39 |
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.39 |
| ▸ | ACE | P12821 | 2/20 | 0.39 |
| ▸ | KRAS | P01116 | 1/20 | 0.39 |
| ▸ | FCGRT | P55899 | 1/20 | 0.38 |
| ▸ | CTSD | P07339 | 1/20 | 0.38 |
| ▸ | MC5R | P33032 | 2/20 | 0.38 |
| ▸ | MC3R | P41968 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24991137 | 0.97 | TSLP (0.43) | FURINTSLPPLK1SIRT2SIRT1 | |
| SCHEMBL24991154 | 0.93 | TSLP (0.44) | FURINTSLPPLK1SIRT2SIRT1 | |
| SCHEMBL24990017 | 0.93 | TSLP (0.44) | FURINTSLPPLK1SIRT2SIRT1 | |
| SCHEMBL24989771 | 0.92 | FURIN (0.45) | FURINTSLPPLK1SIRT2SIRT1 | |
| SCHEMBL24991019 | 0.92 | TSLP (0.48) | FURINTSLPSIRT2SIRT1SIRT3 | |
| SCHEMBL20206341 | 0.91 | FURIN (0.43) | FURINTSLPPLK1SIRT2SIRT1 | |
| SCHEMBL23750043 | 0.90 | TSLP (0.45) | FURINTSLPPLK1MC1RMC4R | |
| SCHEMBL23750094 | 0.90 | TSLP (0.49) | TSLPMC1RMC4RMC5RMC3R | |
| SCHEMBL23750072 | 0.90 | FURIN (0.48) | FURINTSLPSIRT2SIRT1SIRT3 | |
| SCHEMBL24991116 | 0.90 | TSLP (0.44) | FURINTSLPPLK1MC1RMC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230040236-A1 | Diamine-Linked Melanocortin Receptor-Specific Cyclic Peptides for Ocular Indications | PALATIN TECHNOLOGIES, INC. (US) | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230040236-A1 | Diamine-Linked Melanocortin Receptor-Specific Cyclic Peptides for Ocular Indications | MC1R, MC3R, MC5R | FURIN 803/4885TSLP 135/4885PLK1 3519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.